Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2A | Q92830 | 3/20 | 0.41 |
| ▸ | PLA2G6 | O60733 | 2/20 | 0.33 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | FASN | P49327 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4777475 | 0.88 | POLB (0.38) | KAT2APOLBFASN | |
| SCHEMBL8935521 | 0.84 | KAT2A (0.42) | KAT2APLA2G6PLA2G4APOLBFASN | |
| SCHEMBL4304676 | 0.82 | — | — | |
| SCHEMBL5533249 | 0.76 | KAT2A (0.38) | KAT2APLA2G6PLA2G4A | |
| SCHEMBL1023038 | 0.74 | KAT2A (0.38) | KAT2APLA2G6PLA2G4A | |
| SCHEMBL8919082 | 0.72 | KAT2A (0.36) | KAT2APLA2G6PLA2G4A | |
| SCHEMBL26365111 | 0.72 | POLB (0.46) | PLA2G6PLA2G4APOLBFASN | |
| SCHEMBL23554532 | 0.71 | KAT2A (0.35) | KAT2APLA2G6PLA2G4A | |
| SCHEMBL8919099 | 0.71 | KAT2A (0.35) | KAT2APLA2G6PLA2G4A | |
| SCHEMBL7885780 | 0.70 | PRSS1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114615999-B | Drug antibody conjugates | 法马马有限公司 | 2024-03-08 | — | — | CN | disclosed |
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | disclosed |
| CN-114615999-A | Drug antibody conjugates | 法马马有限公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021214126-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2021-10-28 | — | — | WO | disclosed |
| WO-2009136965-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-1919290-A2 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | DMI Biosciences, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1898951-A1 | PHARMACEUTICAL PREPARATION CONTAINING AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A CALCIUM CHANNEL BLOCKER | Daiichi Sankyo Company, Limited (JP) | 2008-03-19 | — | — | EP | disclosed |
| EP-1865964-A1 | TOPICAL FORMULATIONS FOR USE IN THE TREATMENT OR PREVENTION OF DERMATOLOGICAL CONDITIONS | Stegram Pharmaceuticals Limited (GB) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007009087-A2 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | DMI BIOSCIENCES, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007001065-A2 | METHOD FOR THE PREPARATION OF A WET GRANULATED DRUG PRODUCT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-01-04 | — | — | WO | disclosed |
| EP-0900797-B1 | A 1-METHYLCARBAPENEM DERIVATIVE | SANKYO CO (JP) | 2002-08-21 | — | — | EP | disclosed |
| WO-2002057264-A1 | PYRROLE DERIVATES FOR TREATING CYTOKINE MEDIATED DISEASES | SANKYO COMPANY LIMITED (JP) | 2002-07-25 | — | — | WO | disclosed |
| WO-2001002413-A1 | BAFIlOMYCIN DERIVATIVES WITH ANTICANCER ACTIVITY | INSTITUTO BIOMAR S.A. (ES) | 2001-01-11 | — | — | WO | disclosed |
| US-6090802-A | BACTERICIDE | SANKYO COMPANY, LIMITED (JP) | 2000-07-18 | — | — | US | disclosed |
| US-5977097-A | 1-methylcarbapenem derivatives | SANKYO COMPANY LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| EP-0900797-A1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1999-03-10 | — | — | EP | disclosed |
| EP-0882728-A1 | 1-METHYLCARBAPENEM DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0763053-A4 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORP (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0763053-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995033761-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-14 | — | — | WO | disclosed |